PriceTargets.com logo

Pear Therapeutics - PEAR Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PEAR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pear Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PEAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PEAR

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Pear Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for PEAR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Pear Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/20/2023Chardan CapitalDowngradeBuy ➝ NeutralLow
3/20/2023Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
3/17/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
11/16/2022CitigroupLower TargetBuy$7.00 ➝ $5.00Low
11/15/2022Credit Suisse GroupLower TargetOutperform$9.00 ➝ $7.00Low
11/15/2022Chardan CapitalLower TargetBuy$9.00 ➝ $8.00Low
8/12/2022BTIG ResearchLower TargetBuy$11.00 ➝ $5.00Low
8/12/2022Chardan CapitalLower TargetBuy$13.00 ➝ $9.00Low
7/26/2022Credit Suisse GroupLower TargetOutperform$11.00 ➝ $9.00Low
6/24/2022BTIG ResearchLower TargetBuy$12.00 ➝ $11.00Low
6/16/2022Lifesci CapitalReiterated RatingOutperformLow
6/13/2022Chardan CapitalReiterated RatingBuyHigh
5/17/2022Chardan CapitalLower TargetBuy$16.00 ➝ $13.00High
5/17/2022CitigroupBoost TargetBuy$10.00 ➝ $11.00N/A
3/29/2022CitigroupLower TargetBuy$13.00 ➝ $12.00High
1/26/2022Bank of AmericaInitiated CoverageNeutralMedium
1/20/2022Credit Suisse GroupInitiated CoverageOutperform$11.00Low
1/3/2022BTIG ResearchInitiated CoverageBuy$12.00High
12/29/2021CitigroupInitiated CoverageBuy$13.00High
12/22/2021Chardan CapitalReiterated RatingBuyHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Pear Therapeutics logo
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

8 shs

Average Volume

7,748,841 shs

Market Capitalization

$4.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Pear Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Pear Therapeutics in the last twelve months:
View the latest analyst ratings for PEAR.

What is the current price target for Pear Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Pear Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pear Therapeutics in the next year.
View the latest price targets for PEAR.

What is the current consensus analyst rating for Pear Therapeutics?

Pear Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PEAR.

What other companies compete with Pear Therapeutics?

Other companies that are similar to Pear Therapeutics include UpHealth, Ensysce Biosciences, Soligenix, TRACON Pharmaceuticals and Artelo Biosciences. Learn More about companies similar to Pear Therapeutics.

How do I contact Pear Therapeutics' investor relations team?

Pear Therapeutics' physical mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The company's listed phone number is 617-925-7848 and its investor relations email address is [email protected]. The official website for Pear Therapeutics is peartherapeutics.com. Learn More about contacing Pear Therapeutics investor relations.